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INTRODUCTION
INTRODUCTION
About one in 15 people has asthma, a chronic condition whose symptoms are
attacks  of  wheezing,  breathlessness,  chest  tightness,  and  coughing.  This  common
condition  is  a  major  cause  of  lost  workdays  in  adults  and  missed  school  days  in
children. There is no cure for asthma, but most people can control the condition and
lead normal,  active lives.  Different things set  off asthma attacks in different  people.
Smoke from cigarettes or  a fire,  air  pollution, cold air,  pollen,  animals,  house dust,
molds, strong smells such as perfume or bus exhaust, wood dust, exercise, industrial
chemicals;  all  can  trigger  an  attack.  Avoidance  or  reduced  exposure  to  asthma
precipitating  factors  or  triggers  is  obviously  of  great  importance  in  control  of  the
disease.1.2.3.4
Asthma is a highly variable disease where the pattern, frequency and intensity of
symptoms may vary within an individual over  a  period of  time and may also vary
among individuals in duration and severity. While there is no cure for asthma, these
changing characteristics make the management of the disease a challenge for both the
health care professional and patient. Given the highly variable nature of the disease, it is
important that patients have a good understanding of the disease process, are able to
recognize worsening asthma symptoms, and are able to appropriately use and correctly
administer the asthma medications.
Asthma  medications  can  help  prevent  and  control  symptoms,  reducing  the
frequency and severity of asthma exacerbations and reversing airway obstruction. Their
success is depend on their proper use and correct administration.5
Asthma  is  now  one  of  the  world’s  most  common  long-term  conditions,
according  to  the  Global  Burden  of  Asthma  Report,  which  details  the  prevalence,
morbidity, and mortality of asthma in many regions around the world, reveals a number
of alarming facts about the burden of this chronic respiratory disease. The disease is
estimated to  affect  as  many as  300 million people worldwide,  a  number that  could
increase  by  a  further  100  million  by  2025.  Due  to  rapid  industrialization  and
urbanization throughout the region, the prevalence of asthma is predicted to increase
rapidly in the coming years. The increase is likely to be particularly dramatic in India,
which is projected to become the world’s most populous nation by 2050. An absolute
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2% increase  in  the  prevalence  of  asthma in  India  would result  in  an  additional  20
million people with the disease. So it is necessary to make asthma controlled.
Due  to  increasing  incidence  and  prevalence,  primary  care  providers  should
devote much time to caring for patients with asthma. Emphasis should be placed on
evaluating  the  outcome  of  management  in  terms  of  provided  education  to  asthma
patients can improve adherence rates and patient understanding.
Pharmacists have a unique role in the care of these patients with the skills they
possess  to  provide  educational  counseling  and  support  for  quality  of  life  issues.
Historically,  the  majority  of  asthma  related  studies  were  conducted  to  determine
physiologic  measures,  cost  benefts,  and  frequency  of  use  of  hospital  services9 .
However,  relatively  little  information  has  beencollected  on  the  way  patients  with
asthma  feel  and  how  they  function  in  their  day-to-day  lives  10,11.12.13  Investigators
recommended inclusion of quality of life questionnaires in future trials as well as follow
up office visits to evaluate the components which the patient  feels are the most im-
portant.14 There  are  a  few  studies  which  provide  evidence  of  improved  patient
medication adherence as a result of patient  education provided by pharmacists16,17.18..
When patients clarify their perceptions of the effects of asthma, they may be better able
to choose  courses  of  action to  enhance  their  health  and  future.  In  this  manner,  the
pharmacist can begin to assist the patient toward achieving goals that the patient decides
are important for his or her quality of life. Studies have shown that asthma education
programs have a positive impact on treatment outcomes in terms of reducing in number
of  hospital  admissions,  improved  symptoms  and  improved  medication  usage
techniques. These studies have shown that patient education is important in Indian setup
because many patients are illiterate and come from low socio economic barriers9. The
National Health Lung and Blood Institute guideline for diagnosis and management of
asthma advocates that patient education is an essential part in asthma management.20
A mutual  effort  is  required  to  make  the  patient’s  life  more  meaningful  and
personally  fulfilling  when  illness  symptoms  and  physical  restrictions  cannot  be
removed entirely.  Therefore,  the purpose of  this study was to describe the effect  of
asthma in adults within the health care system on their quality of life.
ULTRA COLLEGE OF PHARMACY, MADURAI            PAGE 2
             
The present study aims at assessing the influence of pharmacist provided health
education  on  treatment  outcomes  in  asthma  patients.  As  part  of  the  study  the
knowledge,  attitudes  and  practices  of  asthma  patients  towards  their  disease  and
medication usage, inhaler usage technique and adherence behavior and quality of life of
asthma patients are being assessed.  Here Asthma Control  Test has been used as the
primary outcome as it is a rapid and easy tool to determine the level of asthma control
of patients presenting at community health center and only few studies using ACT as
been conducted in western world.
When managing chronic diseases like asthma measurement of quality of life is
important  as  patients  own experience  of  disease  provides  important  information  on
treatment decisions. In this study mini Asthma Quality Of Life is used as it is short and
easy  to  complete  so  it  is  beneficial  in  Indian  setting  and  it  includes  physical  and
emotional changes that patient experiences which is very important.19
DEFINING ASTHMA
The National Asthma Education and prevention program (NAEPP) of the Heart
and Lung Blood institute defines asthma as a Chronic inflammatory disorder of the
airways in which many cells and cellular elements play a role, in particular, mast cells,
eosinophills,  T-lymphocytes,  macrophages,  neutrophills  and  epithelial  cells.  In
susceptible  individuals,  this  inflammation  causes  recurrent  episodes  of  wheezing,
breathlessness.  chest  tightness  and  coughing,  particularly at  nights  and  in  the  early
morning. These episodes are usually associated with widespread but variable airflow
obstruction that is often reversible either spontaneously or with treatment.20
FACTORS INFLUENCING THE DEVELOPMENT OF ASTHMA
The  factors  that  influence  a  person’s  risk  of  developing  asthma  have  been
identified and are broadly divided into unmodifiable host factors i.e. intrinsic factors
within  an  individual  (genetic  predisposition  to  atopy  and  to  airway  hyper
responsiveness,  obesity  and  gender)  and  modifiable  environmental  factors
(indoor/outdoor  allergens,  respiratory  viral  infections,  occupational  sensitizers,
passive/active smoking, outdoor / indoor air pollution, diet). However, the mechanisms
whereby they influence the development of asthma are complex and interactive. Genes
may interact both with other genes and with environmental factors to determine asthma
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susceptibility.21 In addition, the maturation of the immune response and the timing of
infectious exposures  during the first  years  of life are emerging as  important  factors
modifying the risk of asthma in the genetically predisposed individual.
PATHOPHYSIOLOGY
Airway inflammation is the primary problem in asthma. If the lungs are exposed
to  allergens,  irritants,  cold  air  or  exercise,  inflammatory  mediators  like  histamine,
tryptase,  leu-cotrienes  and  prostaglandins  from  bronchial  mast  cell,  alveolar
macrophages,  T  lymphocytes  and  epithelial  cells  are  released.  The  released
inflammatory mediators  directly cause acute bronchoconstriction and also direct  the
activation of eosinophills and neutrophills, and their migration to the airways, where
they cause injury that result in epithelial damage, airway edema, mucus hyper secretion
and hyper responsiveness of bronchial smooth muscle.21,22
Mechanism
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T- helper lymphocyte is the key in the pathogenesis of bronchial asthma. They
include B cells to synthesise and secrete IgE through the production of interleukin 4(IL-
4) and induce eosinophilic inflammation  via interleukin 5 (IL-5). Mast cells contribute
to  the  inflamatory  reaction  by  the  production  and  release  of  histamine,  tryptase  ,
prostaglandin D2 (PGD2) and leukotriene C4(LTC4). 
These  cells  are  involved  in  the  early  phases  of  asthma  known  as  the  early
reaction. Unlike other types of cells mast cell membranes are stabilized by beta receptor
agonists  (such  as  salbutamol  and  terbutaline)  and  cromones  (such  as  sodium
cromoglycate). 22
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RISK FACTORS
The strongest risk factor for developing asthma is a history of atopic disease. 
Numerous risk factors for asthma have been identified. 
The best studied risk factors including
• Gender
• Airway hyper reactivity 
• Atopy
• Allergens
• Infections
• Tobacco smoke 
• Obesity
• Perinatal factors
• Oxidative stress
• Age
• Weather changes
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o Pollens
In  many  areas  pollens  can  be  a  problem  from  February  to
November each year.  Patients allergic to pollens have to avoid contact
with it. It is important that they should keep all car and house windows
closed and use the air conditioning.
o Animal dander
Pets that have fur or feathers often cause allergy troubles. patients
have  to avoid pets out of home.
Signs and symptoms
Early Asthma Symptoms
Early warning signs are changes that happen just before or at the very beginning49
of an asthma attack. These asthma attack symptoms may start before the well-known
symptoms of asthma and are the earliest signs that your asthma is worsening.
In general, these signs are not severe enough to stop you from going about your
daily activities. But by recognizing these signs, you can stop an asthma attack or prevent
one from getting worse. 
Early warning signs include:
• Frequent cough, especially at night. Losing your breath easily or shortness of 
breath
• Feeling very tired or weak when exercising
• Wheezing or coughing after exercise
• Feeling tired, easily upset, grouchy, or moody
• Decreases or changes in lung function as measured on a peak flow meter
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• Signs of a cold, or allergies (sneezing, runny nose, cough, nasal congestion, sore 
throat, and headache)
• Trouble sleeping
The main symptoms that signal an attack are as follows
• Wheezing
• Coughing
• Shortness of breath
• Chest tightness/pain
Other  nonspecific  symptoms  in  infants  or  young  children  may  be  a  history  of
recurrent bronchitis, bronchiolitis, or pneumonia; a persistent cough with colds; and/or
recurrent croup or chest rattling. 33
DIAGNOSIS OF ASTHMA
A diagnosis  of  asthma  usually  is  based  on  the  patient's  symptoms,  medical
history,  a  physical  examination,  and  laboratory  tests  that  measure  pulmonary  (lung)
function.  Evidence  of  reversible  airway obstruction is  often  detected  in  the  physical
examination or by physiologic testing. Physiologic testing generally is recommended to
confirm the diagnosis. During an asthma attack, wheezing can be heard by listening to
the  chest  with  a  stethoscope.  The  airway obstruction  is  considered  reversible  if  the
wheezing disappears in response to treatment, or when the suspected triggering factor is
removed or resolved.
EPIDEMIOLOGY OF ASTHMA
International Study  of Asthma and Allergies in Childhood (ISAAC) Steering
Committee have demonstrated a wide variation in  the incidence of  asthma and have
shown that the incidence, particularly in children, is increasing. The international pattern
of prevalence cannot be completely explained by our current knowledge of recognized
risk factors for the development of asthma and the reasons for the wide variations in
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prevalence within and between populations remain unknown.
CLASSIFICATION OF ASTHMA SEVERITY 51
The National  Asthma Education and Prevention Program classifies the asthma
severity by following steps (Step 1 to Step 4)
Step 1: labels patients as being ‘mild intermittent’ category of asthma.
This group is defend as having more than 80% of FEVl / FVC ratio and less than
20% of PEF. These patients have symptoms occurring twice a week or less and night
symptoms not more than twice a month
Step 2: classifies patients into “mild persistent” category.
These groups of patients have FEVl FVC ratio is 80% or less than predicted and
PEF value is 20 to 30%. These patients have symptoms occurring more than twice a
week, exacerbations may affect activity and with night symptoms occurring more than
twice a month.
Step 3: categorizes patients into ‘moderate persistent’ category.
This group is defend by having FEVl / FVC ratio more than 60% but less than
80% predicted and  the PEF variability is  more than 30%.  These patients  have daily
symptoms and exacerbations affect the activity. This occurs more than twice a week and
may last for days and with night symptoms occurring more than once a week
Step 4: labels patients as being ‘severe persistent’ category.
These groups of patients are defend by having FEV1 / FVC ratio as 60% or less
than predicted and PEF variability is more than 30%.
ASTHMA PREVALENCE
Studies done by International Institute for Population Sciences (UPS) and Macro
International.  2007 has  shown that  Information in the literature on the prevalence of
asthma is inadequate as most of these studies lack the basic requirements needed for this
type of exercise. These requirements are: adequate sample coverage representing all age
groups, data from different regions in the country and adoption of uniform protocols. The
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NFHS-3 is the only study which meets these requirements.
Hence,  the  results  of  NFHS-3  form  the  basis  for  estimation  of  the  national
prevalence of asthma. 
Asthma prevalence according to National Family Health Survey-3, 2005-06 the
overall prevalence of asthma among adult men and women in India is similar with 1,696
and  1,627  per  100,000  respectively.”  The  number  of  men  and  women  with  asthma
increases  steadily with age.  Prevalence of  asthma is higher  in  rural  areas  (1,719 per
100,000 for women and 1,799 per 100,000 for men) than for urban areas and that it is
more common among women than men. Asthma among men is more prevalent in the
lower wealth quintiles than among the higher wealth quintiles. Moreover, prevalence is
highest among those with less than five years of schooling (2,283 per 100,000 among
women and 2,640 among men per 100,000), and among those with no education (1,914
among women per 100,000 and 2,440 among men per 100,000).
According to World Health Organization report in India, its estimated that 57,000
deaths were attributed to Asthma in 2004.29 Though effective screening, evaluation, and
management strategies for Asthma are well established in high-income countries, these
strategies have not been fully implemented in India as evidence had previously suggested
that Asthma is not to be treated independently but fitted into the general spectrum of
respiratory diseases. Furthermore, even though medicines that treat asthma effectively
are available at affordable costs, they rarely reach more than one per cent of those who
would benefit from it.
MANAGEMENT OF ASTHMA
The National  Asthma Education and Prevention Program (NAEPP), under  the
National Institutes of Health (NIH) National Heart, Lung and Blood Institute (NHLBI),
issued the first Guidelines for the Diagnosis and Management of Asthma in 1991. As
research  advanced  through the  years,  the Guidelines  were  updated,  most  recently as
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Expert  Panel  Re-port3:  Guidelines  for  the  Diagnosis  and  Management  of  Asthma
(EPR3). This research-based report offers step-by-step instructions for treating asthma.
The Guidelines Implementation Panel (GIP) isolated 6 measures that have the
biggest impact on asthma care and patient health.
The  Guidelines  prioritize  steps  to  diagnose  and  individually  treat  asthma
symptoms so that patients require the least amount of medication to achieve maximum
results. Federally funded research and programs have demonstrated repeatedly that the
Guidelines work and save money: Once symptoms are stabilized and causative factors
have been resolved, maintaining symptom-free days and nights becomes routine and cost
effective.
The sooner we adopt Guidelines-level care for all patients, the sooner we’ll start
reducing asthma’s $20 billion annual price tag;  children and families will  experience
fewer symptoms and get back to school and work; and asthma deaths will be eradicated.
6 GIP MEASURES AND ITS IMPORTANCE:
The Guidelines Implementation Panel (GIP) isolated 6 measures they say could
have the biggest impact on asthma care and patient health.
1. Inhaled corticosteroids are the most effective anti-inflammatory medications
for long-term management of persistent asthma.
Inhaled corticosteroids treat the quietly smoldering part of asthma inflammation.
(In-flamed airways are raw, swollen and filed with mucus.) Inhaled corticosteroids are
particularly well suited for people whose stubborn symptoms hang on, even after they
faithfully use other medications, eliminate known allergens and irritants and rule out
interrelated  medical  conditions  such  as  sinus  infections  or  gastro  esophageal  reflux
disease (GERD). Inhaled corticosteroids are usually used daily until physician feel that
the patient can decrease the dose or stop using the medication altogether.
2.All people with asthma should receive a written asthma action plan. Asthma is a
complex,  potentially life-threatening  condition.  Treatment  instructions,  which  include
using  multiple  medications,  responding  to  various  stages  of  symptoms  and  making
environmental changes, must be written in the patient’s record and the patient should get
a  copy.  This  asthma  action  plan  will  cover  routine  or  daily  treatment  as  well  as
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recognizing and handling worsening symptoms. Every person with asthma deserves an
individualized, written asthma action plan.
3. All patients should have an initial assessment that covers impairment and risk
to determine the level of therapy needed.
To decide on a treatment plan, it’s important to take into account how asthma
affects the patient’s daily activities and to assess the risk of future symptoms or life-
threatening events.
4.  At  planned  follow-up  visits,  asthma  patients  should  review  their  level  of
control with their healthcare provider based on multiple measures of current impairment
and future risk in order to guide clinician decisions to either maintain or adjust therapy.
Traditionally,  asthma  was  only treated  in  the  emergency department  or  when
symptoms  were  faring  beyond  your  ability  to  stop  them  at  home.  With  planned,
scheduled visits, patient can focus on good health and work with medical care team to
learn to intervene early and hold on to the best possible breathing levels.
5. Patients who have asthma should be scheduled for planned follow-up visits at
periodic intervals in order to assess their asthma control and modify treatment, if needed.
Planned  follow-up visits  are  important.  After  education and  conversation,  the
office  visit  turns  to  assessing how or  if  the  asthma action plan  should  be  revised  -
specifically, whether or not to adjust the dose and frequency of medications.
The goal: Use the least amount of medication necessary to achieve the maximum
result, meaning asthma doesn’t interfere with your daily life.
6. Clinicians should review each patient’s exposure to allergens and irritants and
provide a multi-pronged strategy to reduce exposure to those allergens and irritants that
make a patient’s asthma worse.
Controlling asthma symptoms involves much more than prescribing medications.
That’s why the guidelines direct clinicians to ask about patients exposures to common
inhalants known to cause airway inflammation such as airborne particles of pet dander,
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tobacco  smoke,  mold,  dust  mites,  cockroaches,  pollen  and other  pollutants  at  home,
work, school and play.
PHARMACOTHERAPY FOR ASTHMA 48
The  medications  used  in  the  treatment  of  asthma  may  be  divided  into  two
categories they are
 Long-term control medications such as
• Inhaled corticosteroids
• Leukotriene modifiers
• Long acting beta agonists
• Combination inhalers
• Theophylline
 Quick-relief medications such as 
• Beta agonists
• anticholinergics 
• systemic corticosteroids.
Long term control medications
• Inhaled corticosteroids. These medications include fluticasone (Flovent Diskus,
Flonase),  budesonide (Pulmicort,  Rhinocort),  mometasone (Nasonex, Asmanex
Twisthaler),  ciclesonide  (Alvesco,  Omnaris),  flunisolide  (Aerobid,  Aerospan
HFA),  beclomethasone (Qvar,  Qnasl)  and  others.  You may need  to  use  these
medications for several days to weeks before they reach their maximum benefit.
Unlike oral corticosteroids, these corticosteroid medications have a relatively low
risk of side effects and are generally safe for long-term use.
• Leukotriene  modifiers. These  oral  medications  —  including  montelukast
(Singulair),  zafirlukast  (Accolate)  and zileuton (Zyflo) — help relieve asthma
symptoms for up to 24 hours. In rare cases, these medications have been linked to
ULTRA COLLEGE OF PHARMACY, MADURAI            PAGE 13
             
psychological reactions, such as agitation, aggression, hallucinations, depression
and suicidal thinking. Seek medical advice right away for any unusual reaction.
• Long-acting beta agonists. These inhaled medications, which include salmeterol
(Serevent)  and  formoterol  (Foradil,  Perforomist),  open  the  airways.  Some
research shows that they may increase the risk of a severe asthma attack, so take
them only  in  combination  with  an  inhaled  corticosteroid.  And  because  these
drugs can mask asthma deterioration, don't use them for an acute asthma attack.
• Combination  inhalers. These  medications  —  such  as  fluticasone-salmeterol
(Advair  Diskus),  budesonide-formoterol  (Symbicort)  and  mometasone-
formoterol  (Dulera)  —  contain  a  long-acting  beta  agonist  along  with  a
corticosteroid.  Because  these  combination  inhalers  contain  long-acting  beta
agonists, they may increase your risk of having a severe asthma attack.
• Theophylline. Theophylline (Theo-24, Elixophyllin, others) is a daily pill  that
helps keep the airways open (bronchodilator) by relaxing the muscles around the
airways. It's not used as often now as in past years.
Most people who have asthma need to take long-term control medicines daily to
help  prevent  symptoms.  The  most  effective  long-term  medicines  reduce  airway
inflammation. These medicines are taken over the long term to prevent symptoms from
starting.  They don’t  give quick relief from symptoms. Inhaled corticosteroids are the
preferred  medicines  for  long-term control  of  asthma.  These  medicines  are  the  most
effective long-term control medicine to relieve airway inflammation and swelling that
makes  the  airways  sensitive  to  certain  substances  that  are  breathed  in.  Reducing
inflammation  helps  prevent  the  chain  reaction  that  causes  asthma  symptoms.  Most
people who take these medicines daily fnd they greatly reduce frequency and severity of
symptoms. Inhaled corticosteroids are generally safe when taken as prescribed. They’re
very  different  from  the  illegal  anabolic  steroids  taken  by  some  athletes.  Inhaled
corticosteroids aren’t habit-forming, even if taken every day for many years. But, like
many other medicines, inhaled corticosteroids can have side effects. One common side
effect  from inhaled corticosteroids is  a mouth infection called thrush. One can use a
spacer or holding chamber to avoid thrush. A spacer or holding chamber is attached to
inhaler when taking medicine to keep the medicine from landing in mouth or on the back
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of the throat.  Rinsing mouth with water  after  taking inhaled corticosteroids also can
lower your risk of thrush.
QUICK-RELIEF MEDICINES
Quick-relief  (rescue)  medications  are  used  as  needed  for  rapid,  short-term
symptom relief during an asthma attack — or before exercise if your doctor recommends
it. Types of quick-relief medications include: 
• Short-acting  beta  agonists. These  inhaled,  quick-relief  bronchodilators  act
within minutes to rapidly ease symptoms during an asthma attack. They include
albuterol (ProAir HFA, Ventolin HFA, others), levalbuterol (Xopenex HFA) and
pirbuterol  (Maxair).  Short-acting beta agonists  can  be  taken  using a  portable,
hand-held inhaler or a nebulizer — a machine that converts asthma medications
to a fine mist, so they can be inhaled through a face mask or a mouthpiece.
• Ipratropium (Atrovent). Like other bronchodilators, ipratropium acts quickly to
immediately  relax  your  airways,  making  it  easier  to  breathe.  Ipratropium  is
mostly used for emphysema and chronic bronchitis, but it's sometimes used to
treat asthma attacks.
• Oral  and  intravenous  corticosteroids. These  medications  —  which  include
prednisone and methylprednisolone — relieve airway inflammation caused by
severe  asthma.  They can  cause  serious  side  effects  when used  long term,  so
they're used only on a short-term basis to treat severe asthma symptoms.
All people who have asthma need a quick-relief medicine to help relieve asthma
symptoms that may fare up. Inhaled short-acting beta2-agonists are the first choice for
quick relief. These medicines act quickly to relax tight muscles around the airways when
patient having a fare up. This allows the airways to open up so that air can flow through
them. Patient  should  take  quick-relief  medicine  when he or  she  first  notices  asthma
symptoms. If patient use this medicine more than 2 days a week, talk with the doctor
about how well controlled your asthma is. Patient may need to make changes in asthma
action plan. The patient should carry quick-relief inhaler with them at all times in case
they need it. If child has asthma, make sure that anyone caring for him or her and the
child’s school has the child’s quick-relief medicines. They should understand when and
how to use them and when to seek medical  care for the child.  Patient  shouldn’t  use
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quick-relief medicines in place of prescribed long-term control medicines. Quick-relief
medicines don’t reduce inflammation.
WHAT IS SPIROMETRY?
Spirometry is a simple test to measure the amount of air a person can breath out
and the amount of time to do so. This test can detect very small changes in lung function
before the patient can appreciate it. This test is useful for the diagnosis and management
of both COPD and Asthma.
Spirometric measurements include:
•  FVC (Forced Vital Capacity):
Maximum Volume of air that can be exhaled during a forced maneuver. It
is  the  volume  of  lungs  from  full  inspiration  to  forced  maximum  expiration.
Expressed as a percentage of the predicted normal for a person
• FEV1 (Forced Expired Volume in One Second):
Volume  Expired  in  the  first  second  of  maximal  expiration  after  a
maximal  inspiration.  This  is  a  measure  of  how  quickly  the  lungs  can  be
emptied.50
Spirometry
The  most  reliable  way  to  determine  reversible  airway  obstruction  is  with
spirometry, a test that measures the amount of air entering and leaving the lungs. This
simple test can be performed in the physician's office. 
Spirometry uses a measuring device called a  spirometer that is connected by a
flexible  tube  to  a  disposable  cardboard  mouthpiece.  The  patient  exhales  and  inhales
deeply, then seals his or her lips around the mouthpiece and blows as forcefully and for
as long as possible until all the air is exhaled from the lungs.
Ideally, the patient should exhale for at least 6 seconds. The spirometer measures
the amount of air exhaled and the length of time it took to exhale it. The amount of air
exhaled in the first second, expressed as "FEV1," is measured and compared to the total
amount exhaled. If the amount exhaled in 1 second is disproportionately low to the total
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exhaled, the patient has an obstruction. To test for reversibility, the patient then inhales a
bronchodilator (i.e., a drug that widens the airways in the lungs) and the spirometry is
repeated. If the values of the test performed after administration of the bronchodilator are
significantly  better  than  the  prebronchodilator  values,  the  obstruction  is  considered
reversible.
Sometimes  a  patient  with  asthma does  not  demonstrate  reversibility after  the
inhalation of a bronchodilator. In this case, the patient may be treated for a few weeks
with anti-inflammatory medications and then returns for another spirometry test. If the
post  treatment  spirometry results  are  better  than the initial  results,  the  obstruction is
considered reversible.
Peak Expiratory Flow
Because  asthma symptoms vary,  it  is  not  unusual  for  a  patient  with  chronic
asthma to have normal spirometry.  In  such cases,  peak expiratory flow (PEF) rate
monitoring may be used to demonstrate reversible airway obstruction. A peak flow meter
is a portable device that can be carried by the patient. It consists of a small tube with a
gauge that measures the maximum force with which one can blow air through the tube.
The patient performs the peak flow meter test twice a day for about 2 weeks and
records  the  results  for  review  in  a  follow  up  appointment.  The  first  test  should  be
performed after waking in the morning, before taking bronchodilator medications. The
patient should perform the peak expiratory flow maneuver 3 times and record the highest
measurement. The second test should be done in the afternoon or early evening after
taking a bronchodilator. Peak flows vary during the day and the early morning peak is
lower than the evening peak. A variability greater than 20% indicates a reversible airway
obstruction.
Bronchial Provocation 
Occasionally, a patient with a suspected asthma-related airway obstruction does
not demonstrate obstruction in spirometry or peak flow monitoring. In this circumstance,
the diagnosis of airway obstruction may be provided by bronchial provocation.
Bronchial  provocation,  also  known  as  bronchoprovocation  and  bronchial
challenge, identifies and characterizes hyper responsive airways by having the patient
inhale an aerosolized chemical, called a broncho-spastic agonist, that triggers a hyper
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responsive reaction. The chemicals most often used are histamine and methacholine.
Patients  perform  spirometry  without  inhaling  the  agent  and  then  inhale
increasingly  higher  doses  of  the  agent.  After  each  incremental  dose  inhalation,
spirometry is performed. Patients who demonstrate a reduction in FEV1 of 20% with a
low dose of methacholine or histamine have nonspecific hyperresponsiveness. Although
some patients  without  asthma demonstrate  hyperresponsiveness,  most patients  with  a
positive reaction have asthma.
The other common bronchoprovocation test is the exercise challenge test, which
is  used  primarily  with  patients  whose  asthma  is  triggered  by  exercise.  The  patient
performs spirometry and then exercises, usually on a treadmill or exercise cycle. The
exercise  test  should  resemble  as  closely as  possible  the  conditions  under  which  the
symptoms are usually triggered. After the patient exercises, spirometry is repeated. This
may be done several times, immediately after exercise and periodically, until there is a
drop in the FEV1 greater than 20% or until 30 minutes have elapsed.
Other Asthma Tests
Tests may be employed to exclude other diseases and to  evaluate conditions that
worsen the asthmatic condition. These include the following: 
• Chest x-rays are often obtained initially to rule out other health conditions. 
• Allergy testing, either by skin testing or by measuring antibodies in the blood,
sometimes is performed to determine if the asthma is allergy induced, and if so,
what specific allergens are involved. 
• X-rays of the sinuses is often done to exclude sinusitis as a factor. 
• Evaluation for gastro-esophageal reflux disease is often performed to evaluate
its contribution to the control of asthma. 
INTERPRETATION
FVC  is  reduced  in  restrictive  disease  and  also  in  obstructive  disease  if  air
trapping occurs. FEV1 is reduced in both restrictive disease and obstructive disease.
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ECONOMIC IMPACT OF ASTHMA 32
Studies done by K.J.R. Murthy et al have shown that majority of patients with
asthma live in rural areas. As poverty levels are higher in rural areas when compared to
urban,  it  is  imperative  that  primary  health  care  providers  should  focus  mainly  on
preventive rather than curative care of the disease and should focus on adopting the
Guidelines for the treatment and management of asthma. The mild and moderate forms
of asthma can be managed successfully even by primary health care providers if they
strictly  follow  the  Guidelines  in  identifying  cases  at  the  early  stages  and  prescribe
medications which are less expensive and ensure quick relief to the patient. Further, as
the treatment is for a prolonged period, the compliance rates would also be high if the
cost of treatment is affordable,  resulting in a lesser number of patients getting into the
acute phase. The estimated total cost of treatment of chronic and acute cases of asthma
according to current practices for 1996 to 2016 is presented in below table.
Additional cost for patients with acute asthma (Rs in crore/year)
The problem of asthma can be easily managed when it is in the mild stage. In
fact, 90% of these cases are mild and can be successfully handled at primary healthcare
centers. This will reduce the financial burden on the family. The remaining 10% of cases
need secondary care. Below table provides the economic burden on patients with chronic
and acute asthma from 1996 to 2016.
YEAR URBAN RURAL TOTAL
1996 27.72 76.71 104.42
2001 44.26 122.51 166.78
2006 64.37 178.19 242.56
2011 87.55 242.36 329.91
2016 111.32 308.26 419.59
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ECONOMIC BURDEN OF ASTHMA ( RS IN CRORE)
Year Chronic Acute Total
1996 960.05 167.07 1127.12
2001 1543.74 267.63 1811.37
2006 2294.73 388.84 2683.57
2011 3197.60 528.84 3726.44
2016 4180.35 672.52 4852.86
CURRENT ISSUES IN ASTHMA MANAGEMENT
The issues associated with asthma management include patient and health care 
professional related issues.
Patient related issues:
According to studies done by  Partridge MR, Osman LM and Horne  many
issues in asthma management are patient-related issues associated with the inappropriate
use of asthma medication. It includes the underuse of preventer medication, the overuse
of reliever medication, non-adherence to treatment regimens and incorrect device use.
Other  patient  related  issues  include  trigger  factor  ignorance,  worsening  asthma  not
recognized and poor perception of asthma control.
Patients’ perceptions,  attitudes  to  and  knowledge  of  asthma  medication  may
influence their self-management in asthma.31,32 Fabbri LM et al  in their study shown
that a poor understanding of asthma and the role of medication has been shown to lead
not only to in-sufficient intake of preventer medication, but also to overuse of reliever
medication that are perceived to be more useful because they provide immediate relief of
symptoms. 33
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Studies by Boulet LP have revealed that a large proportion of people with asthma
do not understand the role of their medications and have many misconceptions and fears
in regard to inhaled corticosteroids and their side effects, reducing their willingness to
use them.32,33,34
It has been shown in a study done by Anis AH et al that asthma patients who use
medication  inappropriately  (specifically  excessive  use  of  short-acting  beta  agonists
combined with underuse of inhaled corticosteroids) are at higher risk for fatal and near
fatal  attacks  and  use  significantly  more  health  care  resources  than  patients  with
appropriate medication use.37
Another  important  patient-related  issue  is  adherence  to  asthma  medication.
According to Bender BG adherence rates to asthma medication in adults are known to
be poor and are frequently less than 50%.38 Many studies such as done by Garg VK et al
have  shown  that  people  with  asthma  are  reluctant  to  use  their  asthma  medication
regularly as recommended. The cost of asthma medication was an issue for nearly two-
thirds of the participants and as a consequence some would not take their medication as
prescribed. In the US, a study found that there were still. Research to identify risk factors
for non-adherence by  Mellins RB et al  has shown factors such as age, sex, objective
measures  of  disease severity,  subject's  educational  level,  complexity of  the treatment
regimen, side-effects, socio-economic barriers and denial of the illness to be associated
with patient's low adherence to therapy.40
Another  important  patient-related  issue  associated  with  medication  use  is  the
incorrect  use  of  asthma  devices.  Inability  to  use  inhalers  effectively  is  known  to
adversely affect  the  delivery of  the  drug  and  thus  minimize  the  benefits  of  inhaled
medication. According to study done by Basheti I et al, in UK and Australia sub-optimal
inhaler  technique  was  demonstrated  by  77%  of  patients  (85%  for  patients  using  a
metered dose inhaler) and patients showed a significant improvement in their inhaler
technique  after  education.41 Previous  studies  by  Nimmo  CJ  et  al,  have  shown  that
written instructions alone are not sufficient for improvements in inhaler technique to be
achieved, and those verbal instructions, demonstrations and practice sessions need to be
included.41,42  Further, it has been shown that inhaler technique tends to decline without
routine review.44
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According to a study done by Gibson PG et al one of the most important patient
related issues of asthma management is self-management of asthma by patients. Self-
manage-ment  involves  the  patient  making  therapeutic,  behavioral  and  environmental
adjustments  in  accordance  with  advice given to  them in advance  by the health  care
provider.  It  has  been  shown  in  various  studies  that  self-management  of  asthma  by
patients  can  reduce  hospitaliza-tions45 and  should  include  self-monitoring,  regular
medical review and use of written action plan. Peak flow-based self-monitoring has been
recommended for those who are poor perceivers of their symptoms.46
To  improve  asthma  management  in  India,  the  following  points  need
consideration:
1. Awareness of asthma as a common and debilitating condition needs to be
improved by government institutions.
2. Inhaled medication should be made available through government 
institutions.
3. Pharmaceutical  companies  should  come forward  to  supply basic  inhalers,
particularly the earlier introduced but effective ones at a lower cost.
4. The  safety,  efficacy,  and  necessity  of  inhaled  steroids  should  be  widely
disseminated among the general public.
5. Simple spirometers and peak flow meters should be made available in all
government institutions
6. Cost-effective and, if necessary, second-best options need to be worked out in
situations where optimum treatment is not affordable or not possible for some
other reason.
HEALTH PROMOTION AND PHARMACISTS:
According to study by Anderson C et al Health promotion is an "umbrella" term
used for a broad range of strategies of which health education is but one part. Health
promotion is defend as any combination of interventions involving health education and
related  (organizational,  economic,  political)  interventions  designed  with  consumer
participation  to  promote  changes  (social,  environmental,  attitudinal,  behavioral)
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conducive to the improvement in health of individuals or groups.47  Health promotion is
not just  about changing lifestyle or providing information.  It  is  also about providing
services that improve the health of individuals and communities, and empowering people
to  have  increased  control  and  to  improve  their  health.  Community  involvement,
ownership and support are crucial in achieving successful health promotion.
ROLE OF PHARMACISTS: 20
According to NIH publication pharmacists may have contact with patients with
asthma who refill  their prescriptions without routine physician care or  who medicate
themselves with over-the-counter (OTC) asthma products. As members of the health care
team, pharmacists are in an excellent position to recognize patients who are not under the
care of a physician or whose asthma may be poorly controlled for a variety of reasons.
Appropriate  therapy and  patient  adherence  will  prevent  most  emergency  department
visits and hospitalizations for asthma. However, when Emergency Department visits or
hospitalizations  occur,  they provide  an  opportunity  for  pharmacists  to  ask  about  the
patient’s treatment plan and to reinforce and clarify instructions that will help prevent the
problem from recurring.
ACTION PLAN FOR PHARMACISTS
1. Educate patients about asthma medications.
2. Instruct patients about the proper techniques for inhaling medications.
3. Monitor medication use and refill intervals to help
identify patients with poorly controlled asthma.
4. Encourage  patients  purchasing  OTC  asthma  inhalers  or  tablets  to  seek
medical care.
5. Help patients use peak flow meters appropriately.
6. Help  patients  discharged  from  the  hospital  understand  their  asthma
management plan.
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1. ACTION PLAN FOR PHARMACISTS
2. There are numerous areas where pharmacists can contribute to improving
health outcomes in patients with asthma. Pharmacists can:
3. 1. Educate patients about the role of each medication.
4. Pharmacists can help patients understand that, with appropriate therapy,
most patients can lead normal, productive, and physically active lives. Pharmacists can
educate patients about the two broad categories of asthma medications:
5. Medications used to prevent and/or decrease the frequency of symptoms.
6. Preventive medication should be taken on a regular basis even when the
patient is free of symptoms. This type of long-term medication includes inhaled anti-
inflammatory sagents  such  as  corticosteroids,  commonly,  and  nedocromil,  which  are
preferred therapy.  It  may include extended-release formulations  of  theophylline.  Also
included  as  long-term medication  are  extended-release  oral  and  long-  acting  inhaled
beta2-ago-nists, which are added to inhaled corticosteroids when the recommended doses
of  inhaled  corticosteroids  are  not  sufficient  to  control  chronic  symptoms,  especially
nighttime  symptoms.  Preventive  long-term  medication  also  may  include,  for  severe
asthma, alternate day oral corticosteroid therapy. In addition, the use of a short- or long-
acting inhaled beta2-agonist or commonly before exercise to prevent exercise-induced
bronchospasm falls into the "prevention" category.
7. Medications taken to relieve asthma symptoms.
8. Medications  in  this  category  are  designed  to  relieve  symptoms  and
generally  are  prescribed  to  be  taken  only  as  needed  (PRN).  This  therapy  includes
primarily  short-acting  inhaled  beta2-agonists  (albuterol,  bitolterol,  pirbuterol,  or
terbutaline). In addition, a short course of oral corticosteroids for patients who are not
fully responsive to inhaled bronchodilators may be used to treat acute exacerbations of
asthma. An effective asthma management plan should ensure that the patient is given
written and verbal instructions that describe when and how a medication should be taken,
how much to take, how to evaluate the response to therapy, when to seek medical care,
and what to do when the desired effect is not achieved or side effects are encountered.
Pharmacists  can  reinforce  these  instructions  by  reminding  patients,  for  example,  to
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contact their physician when acute symptoms are not relieved by using their short-acting
beta2-agonist inhaler as directed or when their peak expiratory flow rate (PEFR) drops
below a predetermined value.
9. 2. Instruct patients about the proper techniques for inhaling medications
10. Inhaled medications are preferred over oral therapies. However, a major
limitation in their effectiveness is the patient's ability to use the device appropriately.
11. Improper MDI technique can be one cause of a poor response to therapy.
Pharmacists can play an important role on the health care team by teaching patients with
asthma about proper medication technique. Other devices, such as dry powder inhalers,
breath-actuated inhalers,  and nebulizers,  are also available,  and they require different
techniques  for  administration.  A  placebo  inhaler,  which  can  be  obtained  from
pharmaceutical manufacturers, and instructional videos may be useful in demonstrating
proper technique.
12. Patients  using  inhalation  therapies  need  careful  instruction,  including
step-by-step demonstration at the time of dispensing the medication, and observation of
their  technique.  Because  inhaler  technique  tends  to  decline  without  routine  review,
pharmacists  should  reassess  a  patient's  technique  when  prescriptions  are  refilled  or
renewed. Patients should be reminded that the most important steps in a proper MDI
technique are gentle exhalation before breathing in, a slow inhalation, and holding the
breath.
13. Pharmacists also should assess whether using a valved spacer device with
an  MDI  would  be  helpful.  Spacers  may  be  beneficial  to  any  patient,  but  they  are
indicated especially for  the patient  who cannot  master  the optimal inhaler  technique.
Spacers are routinely indicated for most patients using a corticosteroid MDI because they
improve particle deposition in the lungs and decrease local side effects such as thrush
and hoarseness.  In  children too young to use an MDI attached to a spacer device,  a
'compressed air-driven nebulizer can be used to administer medications.
14.
15.
16.
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17. 3. Monitor medication use and refill intervals to help identify patients with
poorly con- trolled asthma.
18. American  Academy of  Allergy  and  Immunology  reported  that  during
symptomatic periods, selective short-acting inhaled beta2-agonists may be sufficient to
relieve asthma symptoms. When asthma is stable, it is preferable to use these agents on
an as-needed basis. Overuse and overreliance on short-acting inhaled beta2-agonists can
be signs that asthma is poorly controlled. During an exacerbation, patients may increase
the dose and/or  frequency of  use,  which may lead to a  delay in seeking appropriate
medical  care.  Pharmacists  may  find  indications  of  chronic  overuse  of  short-acting
inhaled beta2-agonists by checking patients' medical history and the frequency of refills.
Overuse can be defined as using more than one canister per month of a short- or long-
acting  beta2-agonist  or  more  than  one  canister  of  a  short-acting  beta2-aganist  in  2
months  when used in  conjunction  with  a  long-acting agent.  Pharmacists  should also
monitor for overuse of a long-acting beta2-agonist (e.g., salmeterol). In general, these
agents should not be used more than twice a day and are not appropriate to relieve acute
symptoms. If overuse is noted, pharmacists should alert the physician, who can assess
the need for reevaluation of the patient and consider whether the patient needs to initiate
or  intensify  anti-inflammatory  therapy.  Before  contacting  the  physician,  pharmacists
should have the patient demonstrate his or her MDI technique. Poor technique may be
one of the causes of overuse of an MDI. The physician will find this information useful
in making a decision on how to respond to the situation. Physicians also may want to
evaluate  recent  trends  in  peak  flow meter  readings.  Physicians  will  consider  several
factors  when  deciding  whether  to  initiate  or  increase  anti-inflammatory  therapy.  In
general, a short course of oral corticosteroids may be indicated if the excessive use of an
MDI is (1) short term; (2) due to an acute, severe episode; or (3) the result of an isolated
exacerbation caused by a common cold or other upper respiratory tract infections. The
initiation  or  dose  increase  of  an  inhaled  anti  -  inflammatory  agent  (corticosteroids,
commonly or nedocromil) as long-term therapy may be indicated if the patient relies on
short-acting inhaled beta2-agonists daily to relieve symptoms, has frequent fluctuations
in the peak expiratory flow rate, or has other signs of poorly controlled asthma.
19. Patients on preventive therapy for asthma also should be monitored for
signs  of  non-adherence  to  anti-inflammatory therapy.  In  some cases,  patients  do not
adhere to anti-inflammatory therapy because they do not understand the purpose of or
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perceive any immediate benefit from this therapy. Some patients may be discouraged
about  following  their  prescribed  regimen  because  they  fear  adverse  reactions  to  the
medications. Refilling the prescription at intervals longer than indicated by the directions
for use on the prescription may indicate non-adherence.
20. 4. Encourage patients purchasing OTC asthma inhalers or tablets to seek
medical care.
21. Asthma is one of the very few potentially fatal diseases for which OTC
products are available for self-treatment. Use of OTC inhalers may lead to a delay in
seeking  appropriate  medical  care.  Pharmacists  should  refer  anyone  using  an  OTC
product for respiratory symptoms to a physician for diagnosis, regular monitoring, and
proper treatment. The physician can then determine the need for other therapies, such as
an  inhaled  anti-inflammatory  agent  to  prevent  symptoms.  Over-the-counter  inhalers
contain  epinephrine,  which  is  a  nonselective,  weak,  and  extremely  short-acting
bronchodilator.  Thus,  if  physicians  determine  that  the  PRN  use  of  an  inhaled
bronchodilator  is  indicated,  they can prescribe a selective short-acting inhaled beta2-
agonist  that  will  provide greater  efficacy and a longer  duration of  action.  Oral  OTC
asthma medications contain ephedrine or a combination of ephedrine and theophylline.
Generally,  bronchodilators  are  less  effective  and  cause  more  side  effects  when
administered by the oral route, and combinations of theophylline and ephedrine have the
potential to cause synergistic toxicity.
22. 5. Help patients use peak flow meters appropriately.
23. It  is  recommended  that  clinicians  consider  peak  expiratory  flow  rate
monitoring for patients over 5 years of age with moderate or severe asthma. Regular
home monitoring may detect decreased lung function and a sign of an impending asthma
episode before it becomes more severe. The PEFR is the greatest flow velocity that can
be obtained during a forced expiration starting with fully inflated lungs. It  provides a
simple, quantitative, and reproducible measure of airway obstruction with a relatively
inexpensive device that is available without a prescription. Measuring PEFR in a patient
with asthma is analogous to measuring blood pressure with sphygmomanometer or blood
glucose to guide insulin dosage. The PEFR is used by the physician to assess the severity
of asthma as a basis for adding medication, monitoring response to chronic therapy, and
detecting deterioration in lung function before symptoms develop. The physician may
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consider more aggressive therapy if the patient's highest value is less than 80 percent of
predicted value  and/or  daily variability is  more  than  20  percent.  Pharmacists  should
discuss the following items with patients: (1) the intended purpose of a peak flow meter
and (2) how to use it and record the values. The patient's physician should develop an
individualized  plan  for  the  use  of  the  peak  flow  meter.  The  plan  should  include  a
threshold value and instructions on what the patient should do if the PEFR drops below
this value (e.g., increase medication, call the physician, or seek emergency medical care).
24. 6. Help patients discharged from the hospital after an asthma exacerbation
understands their asthma management plan.
25. Every patient  being  discharged  from the  hospital  for  the  treatment  of
acute asthma should receive and understand an individualized asthma management plan.
An asthma management plan should include specific written instructions for patients and
families. Hospital pharmacists can discuss such a plan with a patient before discharge,
reinforcing and clarifying instructions that  have been designed to prevent subsequent
hospitalizations  or  emergency department  visits.  Pharmacists  also can review the pa-
tient's   inhaler   and   peak   flow   meter   technique   and   provide   instruction,   if
needed.
26. ASTHMA CONTROL TEST 6
27.Only few of the previous studies by E. Mehuys et al used asthma control as the
main  clinical  outcome  measure.  They  mainly  used  peak  expiratory  flow  or  asthma
severity  as  the  primary  outcome.  Several  of  these  studies  investigated  only  certain
aspects of asthma control.6
28.Furthermore; none of the previous studies in India used asthma control as the
main  clinical  outcome  measure.  However,  current  GINA  guidelines  recommend
evaluating all aspects of asthma control, which is necessary to gain a complete view of
the patients’ asthma-control level, with a clinically validated measure. For these reasons,
it’s necessary to design a feasible intervention focused only on ensuring that patients use
their prescribed drug therapy in the correct way (i.e. correct inhalation technique and
good medication adherence).
29.
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30.Several standardized measures for assessing clinical control of asthma have been
developed,  which  score  the  goals  of  treatment  as  continuous  variables  and  provide
numerical  values  to  distinguish  different  levels  of  control.  Examples  of  validated
instruments are the Asthma control questionnaire, Asthma Control Test, asthma therapy
assessment  questionnaire  and  asthma  control  scoring  system.  To  ensure  that  the
intervention agreed with the new GINA guidelines, the Asthma Control Test was used as
a rapid and easy tool to determine the level of asthma control of patients presenting at
community health center and to provide targeted pharmacist advice.
31. ASTHMA AND QUALITY OF LIFE
32. Greer et al in his study reported that the need for outcome measures other than
morbidity or mortality has been obvious for years. It is, however, very important
to  avoid  simplistic  approaches  to  quality  of  life.  104  Clinicians  and
methodologists should have consensus on the definition of quality of life and the
core component variables.  Quality of  life  instruments  provide physicians  with
valuable information yet these tools are not intended to replace clinical judgment.
Quality of life instruments assist with the structuring and transmission of clinical
information, which actually enhances their credibility.  Asthma is a disease that
imposes a  huge burden on the well-being of  patients and society as a whole.
Quality of life explores general well-being from the different domains of physical
status, psychological impact, and social interactions.105 Quality of life reflects the
perceptions and adaptations to the functional consequences of a chronic disease
like asthma. Clinical and functional variables arguably are only an impairment
that is secondary to chronic conditions. According to study done by Bousquet et
al asthma is a chronic condition in which social life is altered. The importance of
these restrictions on social life can be illustrated by the impairment suffered by
subjects with severe disease or uncontrolled symptoms.10 It is equally well known
that  people  usually  only  consult  their  physician  once  their  quality  of  life  is
affected by their disease106 Asthma treatment is directed towards the improvement
of  a  patient's  health  and  well-being.  Measurements  of  airways  functioning
(spirometry) do not always reflect the amount of disease activity present in the
airways.  Spirometry  correlates  poorly  with  health  and  patients  care  is
complicated by the fact that physicians use different criteria to estimate health.
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Jones et  al  in their study reveal  that  Quality of  life questionnaires provide a
method of quantifying the effect of disease on a patient's life. These instruments
have  the  potential  to  identify  a  threshold  response  to  treatment  that  may be
considered worthwhile and allow for comparisons between therapeutic strategies
with  regard  to  the  health  gain  each  strategy  provides.10 A basic  principle  of
quality of life measurement is that it should be assessed from the view of the pa-
tient. Research evidence suggests that the patient's view of health may change as
the disease progresses and they adjust their perception of what "normal" entails.
A strength of quality of life instruments is  their ability to give a valid global
assessment of the overall effect of the disease on the patient's health and the fact
that they have considerable potential to quantify the magnitude of health gains
from therapeutic strategies.  Objections are that these outcome measures do not
satisfy  accepted  criteria  for  measurement  instruments  such  as  sensitivity,
reliability, validity, responsiveness and acceptability. There is an emerging need
for  measurement  instruments  that  will  capture  changes  that  are  important  to
patients, particularly changes in the quality of life. A person's quality of life is an
important factor to be considered in making decisions regarding effectiveness of
treatment. Quality of life measures provide an opportunity to consider treatment
impacts in various domains: physical, emotional and social. This, in turn, allows
researchers to advance their understanding of underlying biological  and social
processes.  Quality  of  life  instruments  may also  be  able  to  detect  small,  but
important differences that would otherwise remain undetected by less responsive
instruments.
33. The purpose of Measuring Quality of Life
34. Quality of life measures are important when clinical decisions are made.
Patients  should  be  engaged  in  the  process  of  making  treatment  choices.  Measuring
quality of life at a population level helps policymakers to appreciate population trends
when allocating funds. Quality of life outcomes provide a broader perspective showing
the  benefits  and  satisfaction  patients  derive  from  their  treatment.  This  includes
monitoring of change over time and assesses relative impact of alternative treatments.
Quality of life changes can help to monitor the impact of a change in health-care services
on populations under investigation. Quality of life information is also frequently used by
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the pharmaceutical industry and regulatory authorities to decide which drugs or treatment
devices should be developed and marketed, and to assess the relative benefits of various
treatment options. Quality of life assessments as a measure of the effect of disease on a
patient's  health  and  well-being  are  considered  important  tools  in  clinical  studies  on
asthma.
35. The current respiratory symptoms were associated with impaired quality
of life in patients with mild to moderate asthma. Any level of symptom severity had
some effect on quality of life, even in people with occasional symptoms. Although men
and women had the same level of symptom severity, women reported a poorer quality of
life in comparison to their male counterparts.
36.
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Irrespective of a better understanding of the pathophysiology of asthma and its
related  therapeutic  regimes,  the  disease  still  escalates  in  prevalence  and  severity.
According to literatures, a positive relation exists between self-management and quality
of life. However self-management can only be implemented successfully if patients have
enough knowledge. To comprehend the gaps in asthma management, an assessment has
to  be  made  of  the  impact  of  asthma  on  the  individuals  suffering  from  the  disease.
Knowledge about asthma and asthma therapy affects asthma control and, ultimately, the
quality of life of an asthma sufferer. If health professionals can promote appropriate self-
care  methods  the  outcome  may  be  a  relief  on  the  healthcare  system,  with  less
hospitalization for asthma, emergency department visits and presentation at outpatients
departments.
As studies show that many of the issues that still remain in asthma management
are patient related issues associated with the inappropriate use of medication, community
pharmacists  are  ideally  placed  to  provide  services  that  will  help  improve  asthma
management practices in the community. Pharmacists are in a key position to provide
ongoing screening, counseling, monitoring, and education and to reinforce key messages
and provide referrals in view of their therapeutic expertise, accessibility, regular contact
with patients and contact with patients who do not see other health care providers on a
regular basis. They are the last health care professional that the patient sees before they
start using their medication.
Also large  number of  patients  in  rural  areas  have not  yet  benefited  from the
advances in asthma treatment and are still insufficiently controlled, placing severe limits
on daily life and putting them at risk for asthma-related morbidity and mortality. So my
aim of this study was to assess asthma patient’s awareness about disease, medication and
disease management; to study the quality of life of these patients and ultimately to study
the influence of pharmacist provided education on treatment outcomes.
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The present dissertation work was planned to conduct a  "Impact of pharmacist
intervention on health promotion activities in asthmatic patients " and was planned
to be conducted in St.Thomas Hospital, Kollam (District)
The plan of work includes:
I. Submission  of  the  protocol  for  getting  the  approval  from  ethical
committee.
II. To get the consent letter from patients.
III. Select the asthmatic patients for the study.
IV. To design a data collection form
V. To collect the case histories of the asthma patients.
VI. To divide the patients in two group randomly, control and test  groups,
where the test were educated  and control receives education only at the
end of the study.
VII. Select monitoring parameters.
VIII. To evaluated the efficacy profile of drugs.
IX. Carrying out statistical analysis and recorded.
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STUDY DESIGN
This study is a prospective observational study.
STUDY SETTING
The study was carried out on asthma patients visiting the outpatient department in
St.  Thomas  Hospital  at  Kollam district.  It  is  one of  the reputed  Hospital  in  Kollam
district. Majority of patients come from the surrounding rural areas.
Every day approximately 60 patients visit the clinic of which a minimum of 8
patients  are asthmatic.  Altogether a total  of six  physicians,  fifteen nursing staff,  five
pharmacists and five paramedical staffs are providing outpatient services in this center.
SOURCE OF DATA
The required data was collected from the following sources.
 Asthma education profile form containing patient's demographic details
and knowledge questionnaire
 GlaxoSmithKline (GSK) Belgium Asthma control test
 Juniper mini asthma quality of life questionnaire
 Spirometric Evaluation
 Impact of Drug
POPULATION SIZE
A total of 105 patients were enrolled for the study. The patients were randomly
divided into 2 groups,  control  group and the intervention group.  Randomization into
control and intervention group was carried out using block randomization method. Block
randomization  method was  designed  to  randomize  patients  into  groups  that  result  in
equal sample sizes.
INCLUSION CRITERIA
1. Age between 18-60 years.
2. Suffering from asthma disease and those having Asthma Control Test score 
between 15 and 25.
EXCLUSION CRITERIA
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1. Suffering from other severe diseases.
2. Having ACT score < 15 (indicating seriously uncontrolled asthma) or = 25 
(completely controlled asthma, no room for improvement).
3. Pregnancy patients and lactating mothers.
STUDY PERIOD
Study was conducted for a period of 6 months
(February 2013 to July 2013)
ETHICAL APPROVAL
The  Institutional  human  ethical  committee  of  MGR University  approved  the
study.
INFORMED CONSENT
A suitably prepared consent form was used for the purpose of the study.
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METHODOLOGY
STATISTICAL ANALYSIS
Statistical analysis was undertaken with the aid of a statistician. Data was entered
onto a spreadsheet  by the investigator.  Frequency,  mean and standard deviation were
computed. 
DATA COLLECTION TOOL
For the purpose of  the study,  three  instruments were fused and used for  data
gathering purposes
1. Knowledge regarding asthma
Knowledge regarding asthma was assessed by means of a validated questionnaire
(Asthma  education profile questionnaire). A series of statements about asthma and its
management were assessed.
2. Control of asthma
Control of asthma was measured by means of a validated questionnaire (Asthma
Control Test), developed by GlaxoSmithKline (GSK) Belgium.
Subjects  included  were  nocturnal  awakening,  asthma  symptoms,  shortness  of
breath, wheezing and intake of short acting beta stimulants.
3. Quality of life
Quality  of  life  was  measured  by  means  of  a  validated  disease-specific
questionnaire developed  by Juniper. Domains such as symptoms, activity, environment
and emotion were measured.
4. Spirometric Evaluation
FVC & FEV1 values are taken to assess the lung capacity of asthmatic patients.
5. Impact of Drug
The effectiveness of each drug in patient under two groups should be monitored.
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The Asthma Control Test (ACT) was filed out by patients at the baseline and after
first and final follow up. The patient's demographic details were recorded in a suitably
designed data collection form. In order to assess the knowledge of the enrolled patients, a
suitably designed questionnaire, was administrated at baseline and at the final follow up.
In  case  of  patients  using  inhalers,7their  inhaler  usage  technique  was  assessed.  The
Quality  of  life  of  patients  was  evaluated  by  juniper  mini  asthma  quality  of  life
questionnaire  at  the  baseline  and  at  each  follow  up.  In  the  final  follow-up  the
effectiveness of lung capacity in the asthmatic patients can be assessed on the basis of
spirometry and drug impact study.
Patients  in  the  test  group  were  educated  through  verbal  instructions  and  by
providing information leaflets. Whereas the patients in control group received education
only at the end of the study.
Four follow ups were conducted after the baseline with 15 days gap between each
follow-up.
PATIENT COUNSELLING
1. Educate patients about the role of each medication.
2. Instruct patients about the proper techniques for inhaling medications.
3. Monitor medication use and refill intervals to help identify patients with poorly
controlled asthma.
4. Help patients use peak flow meters appropriately. 
5. Encourage patients purchasing OTC asthma inhalers or tablets to seek medical
care.
6. Help  patients  discharged  from  the  hospital  after  an  asthma  exacerbation
understands
their asthma management plan.
7. Patients allergic to pollens have to avoid contact with it. It is important that they
should keep all car and house windows closed and use the air conditioning
8. Pets that have fur or feathers often cause allergy troubles. patients have to avoid
pets out of home.
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STATISTICAL ANALYSIS
Student t test was used to assess the statistical significance of the results. P value 
< 0.05 was considered as statistically significant.
RESULTS
A total of 114 asthma patients, who met the inclusion criteria were, enrolled this
study. These patients were randomized in to test (57 no.s) and control (57 no.s) groups
respectively. Of 114 enrolled patients. 105 patients completed the study. Among them 53
patients in test group and 52 patients in control group have completed all the follow ups.
The remaining 9 patients (5 patients in control and 4 patients in test) were considered as
dropouts because these patients did not come for follow-ups.
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PATIENT DEMOGRAPHICS
No statistically significant difference was observed in the demographics of the
enrolled patients with respect  to age,  gender,  education, smoking history,  occupation,
treatment regimen and duration of asthma were similar in patients of both groups. Patient
demographic details are presented below:
PATIENT DEMOGRAPHICS RESULTS
AGE (BASELINE)
AGE TEST CONTROL
18-20 4 4
21-55 34 34
>55 15 14
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GRAPHICAL REPRESENTATION OF AGE DISTRIBUTION:
TEST CONTROL
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GENDER (BASELINE)
Gender Test Control
Male 31 30
Female 22 22
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EDUCATION (BASELINE)
Educational Status Test Control
Illiterate 3 2
Primary School 13 13
High School + Pdc 34 32
Degree 2 5
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SMOKING HISTORY (BASELINE)
Smoking History Test Control
Smoker 11 9
Ex-Smoker 10 12
Non Smoker 32 31
ULTRA COLLEGE OF PHARMACY, MADURAI                                               PAGE 42
            	  	 
       
DURATION OF ASTHMA (BASELINE)
DURATION(IN YRS) TEST CONTROL
1-5 19 18
6-10 21 24
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>10 13 10
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GRAPHICAL REPRESENTATION OF DURATION OF ASTHMA
(BASELINE)
TEST
CONTROL
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OCCUPATION (BASELINE)
EDUCATIONAL STATUS TEST CONTROL
Employee 17 21
Farmer 9 7
Businessmen 4 3
Student 5 4
Non Worker 18 17
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TREATMENT REGIMEN (BASELINE)
\
TREATMENT REGIMEN TEST CONTROL
INHALER+DRUGS 15 15
DRUGS ONLY 38 37
TEST CONTROL
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ANALYSIS OF KNOWLEDGE RESULTS
The analysis of knowledge results was assessed by the percentage of patients an-
swered  each  item correctly  at  baseline  and  at  final  follow-up (before  and  after  the
education).  The percentage improvement  of  knowledge of patients  in test  group was
observed high compared to the control group. The results are shown in table below:
Sl
No.
Questions
Percentage of Patients
Answered Correctly (At
Baseline)
Percentage Of Patients
Answered Correctly (At
Final Follow Up)
Percentage
Improveme
nt (%)
Control
(N=52)
Test
(N=53)
Control
(N=52)
Test
(N=53)
Con-
trol
Test
N % N % N % N %
1 Are  you  concerned
about  family  members
getting asthma?
6 11.53 5 9.43 11 21.15 28 52.83 9.62 43.4
2 Does asthma affect your
lifestyle?
15 28.84 18 33.96 21 40.38 29 54.71 11.54 20.7
3 Are  you  aware  of  any
effective  treatments  for
asthma?
12 23.07 11 20.75 27 51.92 41 77.35 28.85 56.6
4 Do you think you can do
anything  to  improve
control of your asthma
10 19.23 9 16.98 22 42.30 42 79.24 23.07 67.92
5 Do  you  know  what  is
happening  in  your
airways?
7 13.46 6 11.32 15 28.84 22 41.50 15.38 30.18
6 Do  you  know  what
things  cause  your
asthma to get worse?
15 28.84 10 18.86 23 44.23 43 81.11 15.39 62.25
7 Do  you  know  how  to
avoid  things  that  make
your worse?
7 13.46 8 15.09 16 30.76 45 84.90 17.3 69.81
8 Which  medications  do
you use?
21 40.38 23 43.39 38 73.07 44 83.01 32.69 39.62
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Sl
No.
Questions
Percentage of Patients
Answered Correctly (At
Baseline)
Percentage Of Patients
Answered Correctly (At
Final Follow Up)
Percentage
Improveme
nt (%)
Control
(N=52)
Test
(N=53)
Control
(N=52)
Test
(N=53)
Con-
trol
Test
N % N % N % N %
9 Do you know what each
of  your  medications
does?
5 9.61 4 7.54 15 28.84 43 81.11 19.23 73.57
10 Do  you  ever  forget  to
take your drugs?
10 19.23 12 22.64 23 44.23 41 77.35 25 54.71
11 Do you know how to use
your inhalers properly?
2 13.33 3 20 2 13.33 13 86.66 0 66.66
12 Do you rinse your mouth
after using inhalers? 
5 33.33 6 40 5 33.33 15 100 0 60
13 Do  you  know  how  to
control  asthma  by
looking for symptoms of
worsening asthma 
11 21.15 9 16.98 22 42.30 32 60.37 21.15 43.39
14 Do you have a peak flow
meter? 
0 0 0 0 0 0 0 0 0 0
15 Are  you  confident  you
can usually manage your
asthma symptoms? 
11 21.15 9 16.98 26 50 43 81.13 28.85 64.15
16 Are  you  confident  you
can prevent your asthma
symptoms  from
becoming severe? 
11 21.15 12 22.64 26 50 53 100 28.85 77.36
17 Are  you  confident  you
know what  to  do  when
your  asthma  becomes
worse? 
11 21.15 10 18.86 26 50 45 84.90 39 66.3
18 Do you know when your
asthma is getting worse?
7 13.46 6 11.32 11 21.1 47 88.67 7.69 77.35
In  Asthma  education  profile  questionnaire  more  than  50% improvement  was
shown by test group on questions regarding symptoms, triggering factors, methods to
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avoid them and also proper use of inhalers.
ANALYSIS OF KNOWLEDGE RESULTS
At  baseline  and  in  1st  follow  up,  no  significant  (p  >  0.05)  difference  was
observed in ACT scores of test and control groups. But in the final follow up, the scores
of test group was significantly improved compared to the control group. The scores are
given in table below:
test(mean ± SD) Control (mean ± SD) p value
Baseline 18.06±2.96 18.12±3.10 0.955
First follow up 18.60±3.08 18.06±3.23 0.499
Final follow up 19.26± 3.01 17.98±3.31 0.040
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ANALYSIS OF KNOWLEDGE RESULTS
BASELINE FIRST FOLLOW UP FINAL FOLLOW UP
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NIGHT TIME AWAKENING AS PER ACT SCORE
Group
4 or more
nights a
week(%)
2 or 3
nights a
week
(%)
Once a
week
(%)
Once or
twice (%)
Not at all
(%)
Baseline
Test 11.32 22.64 28.30 24.52 13.20
Control 17.30 13.46 38.46 13.46 17.30
Final fol-
low up Test 1.88 7.54 30.18 18.86 41.50
Control 21.15 26.92 32.69 11.53 7.69
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NIGHT TIME AWAKENING AS PER ACT SCORE
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ASSESSMENT OF MINI AQOL
At baseline and in 1st and 2nd follow up, no significant (p>0.05) difference was
observed in mini AQOL scores of test and control groups. But from 2 follow up to final
follow up, the scores of test group was significantly improved compared to the control
group. The scores are given in table.
Test(Mean ± Sd) Control(Mean P Value
Baseline 4.30± 0.78 4.29 ±0.79 0.955
First Follow Up 4.40 ±0.84 4.30±0.77 0.499
Second Follow Up 4.61±0.68 4.28 ±0.79 0.028
Third Follow Up 4.71±0.63 4.29 ±0.76 0.006
Fourth Follow Up 5.02±0.68 4.29±0.79 0.000
3.8
4
4.2
4.4
4.6
4.8
5
5.2
TEST
CONTROL
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ASSESSMENT OF INDIVIDUAL DOMAINS OF AQOL SYMPTOM 
DOMAIN
Test(Mean ± Sd) Control(Mean ±Sd) P Value
Baseline 3.80± 1.07 3.84 ±1.13 0.844
First Follow Up 3.82 ±1.09 3.87± 1.07 0.826
Second Follow Up 3.91±1.13 3.86±1.13 0.801
Tird Follow Up 3.99±1.15 3.87 ±1.00 0.572
Fourth Follow Up 4.20±1.09 3.85±1.12 0.101
The data did not show any significant difference in physical functioning. 
When viewing from baseline to final follow up there was gradual improvement in 
physical functioning of the test population compared to the control group.
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GRAPHICAL REPRESENTATION OF ASSESSMENT OF
INDIVIDUAL  DOMAINS OF AQOL SYMPTOM DOMAIN
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baseline first follow up second follow up third follow up fourth follow up
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ACTIVITY
No significant difference was found in activity from baseline upto 3rd follow up.
but data in the final follow up showed significant| difference.
Test(Mean ± Sd) Control(Mean ±Sd) P Value
Baseline 4.78±0.71 4.77 ±0.75 0.976
First Follow Up 4.73 ±0.74 4.76± 0.65 0.781
Second Follow Up 4.735± 0.73 4.76 ±0.70 0.814
Third Follow Up 4.77±0.71 4.77 ±0.63 0.982
Fourth Follow Up 5.09±0.82 4.774±0.70 0.032
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GRAPHICAL REPRESENTATION OF ACTIVITY
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EMOTION
At the baseline no significant difference was noted, but from 1st follow up to final
follow up the scores of test group was significantly improved compared to the control
group.
Test(Mean ± Sd) Control(Mean ±Sd) P Value
Baseline 4.54±1.10 4.53 ±1.08 0.967
First Follow Up 4.86 ±1.32 4.54± 1.08 0.180
Second Follow Up 5.44± 0.593 4.52 ±1.075 0.000
Third Follow Up 5.70±0.42 4.55±1.11 0.000
Fourth Follow Up 6.05±0.39 4.538±1.07 0.000
0
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CONTROL
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ENVIRONMENT
At the baseline no significant difference was noted, but from 1st follow up to final
follow up the scores of test group was significantly improved compared to the control
group.
Test(Mean ± Sd) Control(Mean ±Sd) P Value
Baseline 4.07± 0.73 4.02±0.75 0.730
First Follow Up 4.21±0.69 4.01±0.76 0.172
Second Follow Up 4.35± 0.52 4.00 ±0.75 0.006
Third Follow Up 4.40± 0.49 3.99 ±0.73 0.001
Fourth Follow Up 4.75±0.60 4.00±0.74 0.000
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CONTROL
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SPIROMETRY
In the final follow up, the FVC and FEV1 scores of test group was significantly
improved when compared to the control group.
Spirometric values Test (Mean) Control (Mean)
FVC 80.92 77.2
FEV1 77.61 74.24
IMPACT OF DRUG
Based on the drugs taken the patients are classified, and those comes under test
shows a slight improvement in the lung capacity when compared to the control group.
FVC
Drugs Test Control
Asthalin + Deriphylline 77 72
Deriphylline 75.6 69.4
Asthalin 76.6 73.4
Formeterol 78.2 76.5
Budesonide 78.8 76
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IMPACT OF DRUG BASED ON FVC
64
66
68
70
72
74
76
78
80
Test
Control
Drugs
FV
C 
 
Va
lu
es
ULTRA COLLEGE OF PHARMACY, MADURAI                                               PAGE 61
            	  	 
       
IMPACT OF DRUG BASED ON FEV1
FEV1
Drugs Test Control
Asthalin + Deriphylline 77.5 74.5
Deriphylline 75 71.2
Asthalin 73.2 69.8
Formeterol 77.5 74.2
Budesonide 78 77.3
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DISCUSSION
Asthma is a chronic inflammatory disease of the airways. In spite of the advances
made in the management of asthma the morbidity and mortality rates are still  in rise
world-wide.  Besides  the  physician's  efforts  in  controlling  the  disease,  patient's
cooperation is also very important for successful management of asthma. The success of
any medical regimen prescribed for a particular patient often depends, in large part, on
three  factors:  firstly  the  patient's  attitude  towards  the  illness,  including  his  or  her
willingness to work with the physician to manage the disorder: secondly self confidence
of the patient: and the patient's knowledge regarding the illness, which enables him her to
take appropriate action to control particular symptoms. These three factors interact to
contribute to patient's compliance with treatment regimens and the extent to which they
will get involved and participate in their own treatment. This is particularly true for any
chronic disease.
Lack  of  knowledge in  a  patient  with  asthma,  will  results  in  treatment  failure
because the patient will be unaware of the appropriate steps to be taken in managing
his/her disease or the need to avoid triggers. Similarly, if a patient possesses adequate
knowledge but lacks the confidence or to manage an exacerbation the treatment will be
unsuccessful. Similarly if the patient has an uncooperative attitude them treatment may
not  succeed despite  appropriate  medication.  Education is  an important  factor  for  the
success of any self- management program in asthma.
Therefore patient's awareness to their disease and its management are essential to
achieve good asthma control and quality of life. Various research studies have shown that
pharmacist  mediated counselling has  a positive influence on adherence behavior  and
decreased morbidity and mortality.
The present study also has shown that the pharmacist mediated patient education
has  an  influence  on  patient's  knowledge,  attitude  and  practice  towards  the  disease
management,  Asthma Control  Test  and Asthma Quality Of Life improved in the test
group patients compared to the control group patients.
In this study, a total of 105 patients (53 in Test and 52 in Control) have completed
the study. The sample consisted, females 41.5% in test group and 42.3% in control group
and males 58.5% in test group and 57.7% in control group. This showed that males were
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predominant. When participants were categorized into age groups, four subjects in test
group belong to the age group of 18 to 20 years, thirty four subjects belong to the age
group of 21 to 55 years and fifteen subjects belong to the age of 55 to 60 years. This
showed that mostly asthmatics were between the ages of 21 to 55 years. When viewing
the educational status majority of patients in both test (66%) and control (61.5%) group
belong  to  high  school  or  pre  degree  level.  Demographic  details,  like  age,  gender,
education, smoking history, duration of asthma, education status and treatment regimen
were  similar  in  control  and  test  groups  showing  that  the  randomization  done  was
appropriate.
Analysis of asthma education profile questionnaire
Asthma is  a  progressive  disorder,  which  requires  continuous  management  to
control the symptoms. Increased knowledge about the disease and the management may
improve the asthma control in patients. In asthma education profile questionnaire only
the test group was given education but control group did not receive education till the
final follow-up.
The results of asthma education profile questionnaire suggest that patients at the
baseline possess poor knowledge on disease and its management. This may be due to
inadequate information about the disease and medication usage techniques, patient's poor
interest  to  know the disease management.  Studies  were  conducted  about  the  disease
awareness, triggering factors, adherence behavior and inhaler usage technique among the
selected group of patients who received treatment from various practitioners. The results
indicate that increased awareness about the disease and management depends upon the
education provided by the health care professional to the patient.
In the present study, the poor awareness of the patients towards the disease and its
management  can be attributed to inadequate information provided by the health care
professional.  At  the  final  follow up,  the  percentage  improvement  of  knowledge  was
increased  in  test  group  patients  compared  to  the  control  group  patients.  In  Asthma
education profile questionnaire more than 50% improvement was shown by test group on
questions regarding symptoms, triggering factors, methods to avoid them and also proper
use of inhalers. This may be because of pharmacist mediated patient education to the test
group patients. The result suggests that, education provided by health care professional
has a positive influence on patient's disease management attitude.
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Assessment of inhaler usage technique
The results of the present study reveals that patients of both control group and
test  group  could  not  perform all  the  steps  of  inhalers  appropriately  as  indicated  in
standard checklists. In our study we have observed that patients who are on inhalers,
were finding difficulty in performing certain steps such as tilt the head back, exhale as
much as possible,  coordination between actuation and inhalation, continue inspiration
slow and deep, holding the breath for 10 seconds were not performed by many patients at
the baseline in  both control  and test  groups.  These are all  the most  crucial  steps  in
increasing the efficacy of drug in asthma patients. As the education was provided to the
patients of test group regarding the inhaler usage techniques at the baseline and regularly
at each follow-up, the inhalation usage technique was improved in test group patients.
The same was reflected in the results.
Measurement of Primary Outcome
In  this  study  Asthma  Control  Test  was  considered  as  the  primary  outcome.
Awareness of the disease and its management shows a positive influence on the primary
outcome. In the present study a significant improvement in ACT scores were observed.
This  may  be  mainly  because  of  structured  patient  education,  which  suggests  that
education has a positive influence on asthma control. This patient education has resulted
in proper usage of inhalers and reduction in night time awakening in test group compared
to control  group. At the baseline in the test group, there was 11.32% of people were
awakened four or more times in a week and 22.64% of patients awakened two or three
times in a week. After the final follow up the number decreased to 1.88% and 7.54%
respectively.
Findings on mini AQOL
This  study  has  shown  that  pharmacist  mediated  structured  patient  education
found to have significant influence on improvement in the quality of life. Patients in the
test group had shown a significant improvement in their quality of life compared to the
control group patients.
But  when  analyzing  individual  domains  in  mini  AQOL  emotional  and
environmental domain showed significant difference from 1st follow up to final follow
up.  The  assessment  of  emotion  was  calculated  on  feedback  from  aspects  such  as
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frustration  as  well  as  concern  about  asthma and  medication.  Environmental  domain,
evaluated on feedback about bothering regarding dust,  cigarette smoke and pollution.
Both of these domains could be improved by sufficient education and by spending more
time with each patient so that they could speak up about their worries and difficulties
regarding the disease.
Activity domain showed significant improvement only at the final follow up. This
is due to the fact that most of them were reluctant to do mild exercises daily. By step by
step education in each follow up and providing changes in life style modification an
impact was produced at the final follow up.
Symptom  domain  does  not  show  significant  improvement.  But  a  slight
improvement  was observed in  symptom relief  in  the test  group  compared  to  control
group. The pharmacist provided patient education, helped in improvement in all domains
except symptom domain. 
Non-adherence  to  treatment  is  generally  perceived  as  the  preferred  reason
because  of  the  cost  involved  in  purchasing  maintenance  medication  such  as  inhaled
corticosteroids, or long-acting bronchodilators such as salmeterol which are not supplied
in the government system. However, this may have a very negative influence on asthma
quality of life. This also demonstrates why education and health promotion should be
directed at areas that will improve wellness behavior by patients.
Also widespread use of inhaled medication in the developed countries has led to a
reduction in the number of asthma deaths and days off work and off school; improved
quality of life; and has resulted in a paradigm shift in the way an asthmatic considers his
illness.  Despite  the  increasing  knowledge  and  understanding  of  asthma  and  its
management, optimum treatment is apparently not reaching the vast majority of people
in countries like India. A study published in the reputed British journal Thorax notes that
doctors working in poorer countries are unable to use optimum treatment because of the
high cost  and lack of access to medication although they may be fully aware of the
advantages of such treatment.
Secondly, short-term relievers like theophylline and salbutamol are more popular
than inhaled steroids, which, though working more slowly, address the real problem of
in-famed airways in asthma far more effectively. Therefore periodic injections and short
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courses of tablets are more commonly used, which give the asthmatic the illusion that his
disease is not chronic but only an occasional 'allergy' in an otherwise normal lung. This
strategy, unfortunately, can give rise to sudden, severe and occasionally life-threatening
attacks of asthma and can also lead to progressive deterioration of lung function over the
years.
Regular  use  of  inhaled  steroids  over  prolonged  periods  is  considered  to  be
expensive.  In  this  study  out  of  the  105  patients  only  28.51%  are  using  inhaled
medications. Also inhaled medication is not  available from government hospitals and
health centers. Even though few are using inhalers, they are not able to afford the price.
So regular use is impossible for them.
All the above reasons had a negative impact on symptom domain in this study.
Smoking
At the start of the study, nine (17.3%) patients in the control group and eleven
(20.8%)  patients  in  the  intervention  group  reported  to  be  current  smokers.  Of  the
smoking patients in the control group, two had quit smoking, seven were still smoking
after final follow up. Of the smoker in the intervention group, six had quit smoking, five
were still smoking but the frequency was less than earlier after final follow up.
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SUGGESTIONS
1. Individualized  asthma  management  programs  should  be  promoted  in  each
primary, secondary and tertiary care hospitals.
2. Inhaled medication should be made available through government hospitals at
low cost
3. More cooperation is imperative between health-care officials and primary and
secondary care providers in order to develop individualized asthma management
programs that will work at primary care centers.
4. Programs may be conducted to train both hospital and community pharmacists to
control their patients with asthma and other chronic diseases.
5. Awareness  of  asthma  as  a  common  and  debilitating  condition  needs  to  be
improved by government institutions.
6. Pharmaceutical  companies  should  come  forward  to  supply  basic  inhalers,
particularly the earlier introduced but effective ones at a lower cost.
7. The  safety,  efficacy,  necessity  and  techniques  of  inhaled  steroids  should  be
widely disseminated among the general public.
8. Simple  spirometers  and  peak  flow  meters  should  be  made  available  in  all
government hospitals.
LIMITATIONS
• Long term impact of patient education could not be assessed as this study was
carried out for a shorter duration.
• Existing study focused only in improving triggering factors and its prevention,
life style modifications and inhaler technique of patients who attend the clinic.
Other factors of the disease were not included in the present study.
MERITS
Asthma Control  Test  was used as  a  primary outcome,  which incorporates  the
"patient reported outcomes" .This, will serve to shift the focus of control of asthma from
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physician's assessment to patient's own assessment of the disease.
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CONCLUSION
CONCLUSION
This  study  showed  that  improved  patient  knowledge  on  its  own  improve
morbidity  and  mortality.  Enabling  patients  to  identify  problems  by  providing  the
necessary skills, with the assistance of the health care team may revolutionize the world
of asthma.
This study confirmed that knowledge of asthma improved asthma control  and
asthma  quality of life. A good correlation was found between knowledge and asthma
quality of life.
The level of asthma knowledge, degree of asthma control, and asthma quality of
life had to be assessed in this particular population because the baseline knowledge was
needed  to  further  intensify  and  build  a  holistically  appropriate  health  education
programs. The important gaps in knowledge identified by the study, explains why people
are under-treated and have poor asthma control.
In the population studied no association was found between educational status
and  asthma  quality  of  life.  Asthma  interventions  should,  therefore,  target  attitudes,
perceptions, and practical skills that influence day to day practices along with factual
knowledge  to  be  successful  in  reducing  morbidity.  By  improving  problem-solving
capabilities  through  self-management  strategies,  functional  status  may  improve  and
enhance  asthma  quality  of  life.  Good  quality  of  life  leads  to  positive  expectations
regarding the outcome of the disease and will, therefore, reduce fear and anxiety. All of
these aspects will improve asthma morbidity and give patients the confidence to self-
regulate their disease
The research carried out in this work utilized the skills and therapeutic expertise
of  the  pharmacist  in  the  current  environment,  to  develop  an  asthma outreach  health
promotion in a rural setting .Pharmacist provided asthma education has been shown to be
effective  as  individualized  education was better  received by patients.  Further,  it  also
showed that individualized asthma education is more effective for certain outcomes such
as inhaler technique and physical activity
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This study also addresses the issue of asthma management in the Indian rural
setting. In rural area, asthma management practices have been shown to be poorer and
asthma mortality rates considerably higher than those of metropolitan areas. There are a
limited number of accesses to health care services and shortages in specialist services are
increasing the asthma. The chronic shortage of medical practitioner's results in extremely
long waiting times, and often patients fail to approach health care practitioners due to
difficulty of access. Therefore,  it becomes paramount that people with asthma in rural
areas  become involved in self-management  of  their  asthma and that  the community-
based  health  care  providers  be  more  proactive  in  facilitating  these  self-management
behaviors.
In India, the involvement of community pharmacists in asthma health promotion
or outreach programs has  been limited,  despite  the beneficial  effects associated with
these pro-grams in improving asthma outcomes. The work completed in this thesis shows
that pharmacists can effectively deliver asthma outreach programs in rural settings which
result in an increase in asthma awareness and an improvement in asthma knowledge,
which can result in an improvement in patient asthma outcomes.
It can therefore be concluded that in our country, interactions with pharmacists
hold great potential.
An  important  element  to  this  study  was  that  it  demonstrated  the  need  for
collaboration  between  the  health  care  professionals  in  order  to  be  able  to  achieve
successful asthma outreach health promotion.
Future works should involve, engaging more pharmacists to deliver these roles on
a larger scale across India. Also strengthening aspects other than knowledge to enhance
asthma  control  might  be  beneficial  for  proper  asthma  management.  For  health  care
providers, the aim should be to empower people suffering from asthma to be responsible
and confident enough to control their own disease. Apart from therapy patients should be
involved  in  self-management  plan.  Self-management  will  also  increase  patients'
knowledge and awareness about asthma and its treatment because people will learn what
to  do  when  they  are  well  and  when  they  are  symptomatic  .The  credibility  of  such
programs will also increase if health professionals give attention to patient's beliefs or
their goals to satisfy their specific needs.
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In India, asthma is on rise and still remains a mystery, to unravel this it needs a
lot of study, involvement of health care professionals and patients and of course asthma
control should be a habit.
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